Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Biomarker Partnering Terms and Agreements

Biomarker Partnering Terms and Agreements - new market research report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-01-23 13:52:02 - Biomarker Partnering Terms and Agreements - a new market research report on companiesandmarkets.com

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to

 

 

license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 800 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007. The chapter is organized by specific diagnpstics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

Trends in biomarker dealmaking in the biopharma industry since 2007
Analysis of biomarker deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life biomarker deals
Access to several biomarker contract documents
The leading biomarker deals by value since 2007
Most active biomarker dealmakers since 2007
The leading biomarker partnering resources

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 800 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise biomarker rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com